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Original article
Purpose: Sex hormone-binding globulin (SHBG) modulates the availability of 
biologically active free sex hormones. The regulatory role of SHBG might be important 
in the relationship between hormone levels and the modification of lipid profiles in 
girls with precocious puberty. However, few studies have evaluated the relationship of 
SHBG, free estradiol index (FEI), and lipid levels in these girls.
Methods: One hundred and nine girls less than 8 years of age with pubertal 
development were enrolled. FEI was calculated with SHBG and estradiol (E2). We 
analyzed SHBG between peak luteinizing hormone (LH)≥5 (IU/L) (group 1) and LH＜5 
(IU/L) (group 2) through a gonadotropin releasing hormone stimulation test.
Results: Body mass index (BMI) standard deviation score (SDS) was higher in group 2 
than in group 1 (P=0.004). Serum SHBG levels did not differ and FEI was not higher in 
group 1 (P=0.122). Serum cholesterol, HDL, and LDL did not differ; however, triglyceride 
levels were higher in group 2 (P=0.023). SHBG was negatively correlated with bone age 
advancement, BMI, BMI SDS, and FEI, and was positively correlated with HDL. However, 
SHBG was not correlated with E2 or peak LH. 
Conclusion: Serum SHBG itself might not be associated with precocious puberty in 
girls, but it might be related to BMI and lipid profiles. Further studies are needed to 
reveal the relationship between sex hormone and obesity in girls with precocious 
puberty.
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Introduction
Sex hormone-binding globulin (SHBG) is a glycoprotein that binds to sex hormones such as 
androgens and estrogens1). Most of SHBG bind over 97% of testosterone and estradiol (E2)2). 
When checking serum E2, a total level includes free and bound forms. A free estradiol index 
(FEI) expresses the ratio of E2 to SHBG and can be used to summarize the activity of free 
forms of E2. Thus, the concentration of SHBG is a major constituent regulating distribution 
of sex hormones between the protein-bound and free states3), and the bioavailability of sex 
hormones is influenced by the level of SHBG4). 
It is known that various conditions with low SHBG include hypothyroidism, Cushing 
syndrome, polycystic ovary syndrome, diabetes and obesity5). The level of SHBG was high in 
girls with premature thelarche6). Low levels of SHBG at menarche have been reported in girls 
with constitutionally delayed puberty7). The oral contraceptive containing ethinylestradiol 
administration increases SHBG level8). Early childhood is characterized by high levels of 
SHBG with a gradual decline as puberty approaches9,10).
SHBG might have important role in the progress of precocious puberty, but few studies 
evaluated the relationship in girls with precocious puberty. The first aim of this study was to 
evaluate the association between sex hormones and SHBG in girls with idiopathic central 
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precocious puberty. We compared the difference of SHBG 
between peak luteinizing hormone (LH)≥5 group and LH
＜5 group through gonadotropin releasing hormone (GnRH) 
stimulation test. Second, we investigated the relationship 
between weight, lipid profiles and SHBG. 
Materials and methods
A total of 109 girls with pubertal development aged under 
8 years at Gangnam Severance Hospital were included in this 
study from January 2010 to August 2011. We reviewed the 
records of all the girls with premature sexual development 
who underwent GnRH stimulation tests retrospectively. The 
inclusion criteria for this study were objective breast budding 
before the age of 8 years, more than Tanner stage 2 by one 
pediatric endocrinologist and advanced bone age over the 
chronological age. The subjects with an identified etiology, such 
as brain tumor or hypoxic damage, were excluded.
Height was measured by a stadiometer (Harpenden Ltd., 
Crymych, UK) to the nearest 0.1 cm. Weight was measured on a 
digital scale with a precision of 0.1 kg (SECA, model 707). Body 
mass index (BMI) was calculated as weight (kilograms) divided 
by height (meters) squared.
The hypothalamic-pituitary-gonadal axis was investigated 
by GnRH stimulation test. Basal serum samples were obtained 
prior to the GnRH (100 μg Relefact; Sanofi-Aventis, Frankfurt, 
Germany) injection. Post stimulation samples for measurements 
of LH, FSH, and E2 levels were acquired at 30, 60, 90 and 
120 minutes after the GnRH injection. Serum LH and FSH 
levels were measured by immunoradiometric assay (IRMA) 
with analytical sensitivity of 0.2 IU/L (BioSource, Nivelles, 
Belgium). The E2 levels were determined by radioimmunoassay 
with analytical sensitivity of 5 pg/mL (RIA; Coat-A-Count, 
Diagnostic Products, Los Angeles, CA, USA). SHBG was 
determined by a immunofluorescence assay (Delfia, Wallac Oy, 
Turku, Finland). FEI was calculated by dividing the serum E2 
level by the serum SHBG level and multiplying by 100. A peak 
LH of at least 5 IU/L was used as the cutoff criteria for pubertal 
response through the GnRH stimulation test.
Data were analyzed by the SAS 9.1 (SAS Institute Inc., Cary, 
NC, USA). Two sample t test or Mann-Whitney U  test were 
performed to compare the clinical parameters of the subjects 
in between groups. Pearson correlation for SHBG and peak 
LH was examined. To determine significant association 
with pubertal response, linear regression was performed 
with univariate and multivariate analysis. Significance was 
determined as P＜0.05. 
This study was approved by the Institutional Review Board of 
Yonsei University Gangnam Severance Hospital (IRB number 
3-2011-0314). Written informed consent was exempted from all 
subjects as well as their parents.
Results
Baseline patient characteristics between peak LH≥5 (group 
1) and LH＜5 (group 2) through GnRH stimulation tests are 
shown in Table 1. BMI standard deviation score (SDS) was 
higher in group 2 than group 1 (P=0.004). Serum E2 and SHBG 
levels were not different in both group. FEI were not higher in 
group 1 (P=0.122). Serum cholesterol, high-density lipoprotein 
(HDL) and low-density lipoprotein (LDL) were not different, 
however, triglycerides levels were higher in group 2 (P=0.023).
From the analysis of Pearson correlation in group 1, SHBG 
was negatively correlated with bone age (BA) advancement, 
BMI, BMI SDS, FEI, and positively with HDL (Table 2). 
However, SHBG was not correlated with E2 and peak LH. 
Table 3 shows association between peak LH and measure-
ments in group 1 through multiple regression analysis. BA, BMI 
SDS, FEI, cholesterol, triglycerides and SHBG did not show 
significant correlation with peak LH. We performed multivariate 
Table 1. Baseline characteristics  of patients according to peak LH level through a GnRH stimulation test
Characteristic LH≥5 (IU/L) (n=54) LH<5 (IU/L) (n=55) Total (n=109) P-value
CA (yr) 8.1±1.3 8.2±1.4 8.1±1.3 0.541
BA (yr) 9.1±1.6 9.0±1.5 9.1±1.7 0.324
BA–CA (yr) 0.99±0.69 0.94±0.70 0.97±0.69 0.734
BMI SDS 0.17±0.78 0.77±1.33 0.45±0.56 0.004
Peak LH (IU/L) 12.4±6.4 2.9±2.1 8.9±5.8 0.001
E2 (pg/mL) 19.0±15.7 14.2±9.6 16.8±12.1 0.056
FEI (pmol/L) 27.9±24.8 21.5±20.0 24.8±22.9 0.122
SHBG (nmol/L) 85.9±30.6 80.9±37.8 83.2±36.4 0.428
IGF-1(μg/L) 258.0±92.9 206.6±64.0 227.6±88.7 0.002
Cholesterol (mg/dL) 158.3±23.6 152.8±17.8 155.8±21.9 0.203
HDL (mg/dL) 53.0±10.0 49.7±10.1 51.5±10.1 0.082
LDL (mg/dL) 88.4±20.2 81.8±15.1 84.9±17.8 0.104
Triglycerides (mg/dL) 85.6±42.7 112.2±72.0 101.1±61.9 0.023
Values are presented as mean±standard deviation.
LH, luteinizing hormone; GnRH, gonadotropin releasing hormone; CA, chronologic age; BA, bone age; BMI, body mass index; SDS, 
standard deviation score; E2, estradiol; FEI, free estradiol index; SHBG, sex hormone binding globulin; IGF-1, insulin like growth factor 1; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
83
Chae HW, et al. • Sex hormone binding globulin in girls with precocious puberty
www.e-apem.org
logistic regression of variables associated with peak LH and 
calculated odds ratio (Table 4). BA advancement, BMI SDS, 
cholesterol, triglycerides and SHBG did not show significant 
results.
Discussion
1. Association between sex hormones and SHBG in
   girls with precocious puberty
In the present study, the SHBG levels were not higher in 
pubertal response group than nonpubertal response group, 
and SHBG did not show significant correlation with peak LH. 
There are various studies about conditions influencing levels of 
SHBG. It decreases with high levels of insulin, growth hormone, 
insulin-like growth factor 1, androgens and prolactin5,11). High 
estrogen and thyroxine cause it to increase8). From this point of 
view, it seemed to be appropriate that the levels of SHBG might 
increase in girls with precocious puberty. However, Sorensen 
et al.4) showed that 25 girls with idiopathic central precocious 
puberty had lower levels of SHBG at diagnosis compared with 
controls. The study showed that the low SHBG levels decreased 
further during the 24-month with GnRH agonist treatment 
for central precocious puberty, and no tendency toward 
normalization was observed4).
The levels of SHBG in girls with central precocious puberty 
are not uniform like this. It is unclear how SHBG is associated 
with sex hormones in precocious puberty. We can consider 
various factors affecting SHBG levels in girls during puberty. 
First, alteration of the androgen-estrogen balance during 
precocious pubertal development can affect the levels of 
SHBG12). The subtle decreases in plasma SHBG levels during 
puberty have a perceptible effect on the androgen-estrogen 
balance5). Second, changes in body mass and composition are 
also major determinants of plasma SHBG levels, particularly in 
girls during puberty13,14). It might be confounding factors that 
BMI SDS was higher in nonpubertal response group in this 
study. 
2. Association between weight, lipid profiles and
   SHBG in pubertal response group
SHBG was negatively correlated with weight, BMI, BMI 
SDS, and positively with HDL in pubertal response group. 
Our results coincide with previous reports. In women, low 
circulating SHBG was found to be associated with an increased 
accumulation of abdominal fat and body fat mass15,16). There are 
various studies that plasma level of SHBG has emerged as one 
of the most important correlates of obesity-related metabolic 
complications17). Reduced SHBG level in women has also been 
associated with an adverse blood lipid profile, including reduced 
HDL cholesterol18,19). Furthermore, low circulating SHBG was 
associated with glucose intolerance, insulin resistance, as well 
as with the risk of cardiovascular disease and type 2 diabetes 
in women18,20). The observed correlations might support the 
hypothesis that SHBG might have roles associated with obesity 
related risk factors in girls with precocious puberty, however, 
few studies evaluated the relationship.
This study has several limitations. First, the present study 
is the just cross-sectional study with small sample size. The 
total number of patients was 109, and the number of pubertal 
response group was only 54. Future studies of the effects of 
SHBG on the development and progression of precocious 
Table 2. Pearson correlation for SHBG and peak LH peak in 
pubertal response group
SHBG Peak LH
Correlation 
coefficient (r ) P-value
Correlation
coefficient (r ) P-value
SHBG –0.132 0.161
BA-CA –0.231 0.014 0.147 0.123
Weight –0.396 0.002 0.274 0.036
BMI –0.291 0.025 0.228 0.083
BMI SDS –0.257 0.049 –0.073 0.442
E2 –0.205 0.119 0.368 0.001
FEI –0.538 0.001 0.309 0.001
Cholesterol 0.149 0.120 0.168 0.079
LDL 0.181 0.208 0.120 0.246
HDL 0.260 0.010 0.128 0.211
Triglycerides –0.073 0.475 –0.132 0.195
SHBG, sex hormone binding globulin; LH, luteinizing hormone; 
BA, bone age; CA, chronologic age; BMI, body mass index; SDS, 
standard deviation score; E2, estradiol; FEI, free estradiol index; 
LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Table 3. Multiple regression analysis: Associations between peak 
LH and measurements in the pubertal response group
Standardized coefficients ß t P-value
BA 0.058 0.366 0.716
BMI SDS 0.059 0.279 0.782
FEI –0.299 –1.594 0.119
Cholesterol –0.187 –1.100 0.278
Triglycerides –0.118 –0.641 0.525
SHBG –0.028 –0.134 0.894
LH, luteinizing hormone; BA, bone age; BMI, body mass index; 
SDS, standard deviation score; FEI, free estradiol index; SHBG, sex 
hormone binding globulin.
Table 4. Multivariate logistic regression of variables associated 
with peak LH
Variable Odds ratio 95% CI P-value
SHBG 0.993 0.98–1.01 0.903
BA–CA 0.892 0.36–2.24 0.812
BMI SDS 3.337 0.21–52.40 0.393
Cholesterol 1.018 0.95–1.07 0.746
Triglycerides 0.991 0.97–1.00 0.117
LH, luteinizing hormone; CI, confidence interval; SHBG, sex 
hormone binding globulin; BA, bone age; CA, chronologic age; 
BMI, body mass index; SDS, standard deviation score.
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puberty should include large data through longitudinal study. 
Second, our data did not include other associated factors, such as 
insulin. Insulin is a potent inhibitor of SHBG, and SHBG might 
be a marker of hyperinsulinemia and insulin resistance5,21). More 
accurate analysis including various hormones should be needed 
to identify the relationship between precocious puberty and 
obesity.
In conclusion, serum SHBG itself might not be associated 
with precocious puberty in girls, but it might be related with 
weight, BMI and lipid profiles. Large number of longitudinal 
studies are needed to reveal relationship between sex hormone 
and obesity in precocious puberty.
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